|
|
| Type |
Poster Presentation |
| Area |
Medicinal Chemistry |
| Room No. |
Grand Ballroom |
| Time |
10월 18일 (목요일) 11:00~12:30 |
| Code |
MEDI.P-284 |
| Subject |
Studies on SHP2 inhibitors for Cancer Treatment |
| Authors |
Bohee Kim, Seungjin Jo1, Jeong-Hun Sohn, Byumseok Koh1, Inji Shin1,*
Department of Chemistry, Chungnam National University, Korea
1Therapeutics & Biotechnology Division, KRICT, Korea
|
| Abstract |
SHP2, non-receptor protein tyrosine phosphatase encoded by PTPN11 gene, plays an important role in the control of cell growth, oncogenic transformation and differentiation. Activating mutations of SHP2 have been reported as a cause of Noonan syndrome and several cancers, such as leukemia or breast cancer. The discovery of SHP2 inhibitor can be a therapeutic candidate for the treatment of cancers and SHP2 associated diseases. Studies on a small molecule targeting protein tyrosine phosphatases (PTPs) have been challenged due to polarity of the catalytic site. Therefore, discovery of an allosteric inhibitor can be a good alternative to an active site inhibitor.
Herein, we present our research on SHP2 inhibitors. Through high-throughput screening (HTS), we identified a ‘hit’, and further study is currently in progress.
|
| E-mail |
bohee@krict.re.kr |
|
122nd General Meeting of the KCS